Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 1/20 | 0.60 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.46 |
| ▸ | CTSG | P08311 | 1/20 | 0.45 |
| ▸ | CMA1 | P23946 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16572402 | 0.87 | MEN1 (0.55) | KCNN4KCNA3GAAPKMALDH1A1 | |
| SCHEMBL31287301 | 0.87 | MEN1 (0.55) | KCNN4KCNA3GAAPKMALDH1A1 | |
| SCHEMBL5708819 | 0.86 | GAA (0.62) | GAAPKMALDH1A1LMNAUSP2 | |
| SCHEMBL25422392 | 0.81 | HDAC1 (0.46) | KCNN4KCNA3GAAPKMALDH1A1 | |
| SCHEMBL13171923 | 0.81 | KCNN4 (0.46) | KCNN4KCNA3GAAPKMALDH1A1 | |
| SCHEMBL5796536 | 0.81 | HDAC1 (0.46) | KCNN4KCNA3PKMALDH1A1LMNA | |
| SCHEMBL21315085 | 0.79 | KCNN4 (0.47) | KCNN4KCNA3GAAPKMALDH1A1 | |
| SCHEMBL29191634 | 0.78 | KCNN4 (0.49) | KCNN4KCNA3GAAPKMALDH1A1 | |
| SCHEMBL13171921 | 0.78 | PKM (0.44) | KCNN4KCNA3GAAPKMALDH1A1 | |
| SCHEMBL16503316 | 0.78 | KMT2A (0.44) | KCNN4KCNA3PKMALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041690-A1 | Co-Administration of Dopamine-Receptor Binding Compounds | DARPHARMA, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20070254906-A1 | Method of Administration of Dopamine Receptor Agonists | DARPHARMA, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070155720-A1 | Co-administration of dopamine-receptor binding compounds | DARPHARMA, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| WO-2006012640-A2 | METHOD OF ADMINISTRATION OF DOPAMINE RECEPTOR AGONISTS | DARPHARMA, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| EP-0845988-B1 | NOVEL FUSED ISOQUINOLINES AS DOPAMINE RECEPTOR LIGANDS | PURDUE RESEARCH FOUNDATION (US) | 2001-12-05 | — | — | EP | disclosed |
| US-6194423-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | PURDUE RESEARCH FOUNDATION | 2001-02-27 | — | — | US | disclosed |
| US-5959110-A | SUBSTITUTED TETRAHYDRO-1H-NAPH(1,2,3-DE)ISOQUINOLINE COMPOUND USEFUL FOR TREATING NERVOUS SYSTEM DISORDERS | PURDUE RESEARCH FOUNDATION (US) | 1999-09-28 | — | — | US | disclosed |
| CN-1199338-A | Novel fused isoquinolines as dopamine receptor ligands | PURDUE RESEARCH FOUNDATION (US) | 1998-11-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041690-A1 | Co-Administration of Dopamine-Receptor Binding Compounds | DRD2, DRD1, DRD3 | KCNN4 1286/4885KCNA3 656/4885GAA 1590/4885 |
| US-20070254906-A1 | Method of Administration of Dopamine Receptor Agonists | ADRA1D, DRD2, CHRM3 | KCNN4 1093/4885KCNA3 1150/4885GAA 1737/4885 |
| US-20070155720-A1 | Co-administration of dopamine-receptor binding compounds | DRD2, DRD1, DRD3 | KCNN4 1275/4885KCNA3 660/4885GAA 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.